| This week's sponsor is RAPS. | | | |
Today's Rundown Shire snaps up Bayer’s Andreas Busch a day after he leaves the German pharma Astellas buys DMD drug in $450M mitochondrial takeover Active Bio and Teva’s laquinimod strikes out again, this time in progressive MS [Sponsored] What makes a modern-day biotech? ValiRx shares yo-yo on fundraising and pipeline update Foundation Medicine gets FDA, CMS nods for pan-cancer genomic test EuroBiotech Report—Merck-Brexit, Innate-BMS, UCL-Synpromics, MorphoSys and Auris FiercePharmaAsia—Takeda’s assets spinoff, AstraZeneca’s China JV, Biocon’s biologics plant Chutes & Ladders—Teva rejigs C-Suite amid major restructuring Featured Story | | | Friday, December 1, 2017 Bayer was keeping mum on where its R&D vet Andreas Busch, Ph.D., was heading yesterday after it announced a big change-up in its research unit (and his exit), but early this morning Shire announced it was the company he was heading for. |
|
|
| This week's sponsor is Charles River. | | | |
Top Stories Friday, December 1, 2017 Astellas has acquired its partner Mitobridge in a deal worth up to $450 million. The takeover gives Astellas full control of a phase 1 Duchenne muscular dystrophy (DMD) drug in return for $225 million upfront and the same again down the line. Friday, December 1, 2017 Active Biotech and Teva’s laquinimod—once billed as a successor to multiple sclerosis blockbuster Copaxone—has hit yet another snag after failing a phase 2 trial in primary progressive MS. Monday, November 27, 2017 Blue Latitude Health interviews 6 biotech leaders to reveal the commercial challenges and opportunities in 2018 and beyond, including big data, FDA approvals, combination therapies, empowered patients and the skills crisis. Friday, December 1, 2017 ValiRx is approaching a pivotal point in its development as it waits for clinical results from two lead programs that it hopes will net it a development partner. Friday, December 1, 2017 Foundation Medicine has brought its pan-cancer test through the parallel review process, securing FDA approval and a likely coverage by Medicare. The approval is the first time the FDA has signed off on such a broad test. Thursday, November 30, 2017 In this week's EuroBiotech Report, Merck bets on post-Brexit Britain, Innate rocked by lirilumab setback, UCL inks gene therapy pact and more. Friday, December 1, 2017 Takeda transferred some early cancer candidates to a startup it's incubating, AstraZeneca put its R&D capabilities in China in the hands of a newly formed joint venture, Biocon has resolved FDA concerns of a plant crucial to potential approval of its Herceptin biosimilar, and more. Friday, December 1, 2017 Teva CSO Hayden will leave with two other executives amid a major structural overhaul, Bayer R&D reorg saw Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs, plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. BioBasics: Biotech for the Non-Scientist November 30-December 1, 2017 | Boston, MA FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA BIO Asia International Conference March 19-20, 2018 | Tokyo, Japan Molecular Med Tri-Conference February 11-16, 2018 | San Francisco, CA BIO CEO & Investor Conference February 12-13, 2018 | New York, New York | 